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Skin of color, which refers to individuals with Fitzpatrick skin types
(FST) IV through VI, represents a rapidly expanding population in
the United States as well as in many nations across the world. It in-
cludes Asians, Latinos (Hispanics), Africans, African-Americans,
Afro-Caribbeans, Middle Easterners, Native Americans, Alaskan na-
tives, Paciﬁc Islanders, Native Hawaiians and Mediterraneans. In the
United States alone, just over one third of the United States population
reported their race and ethnicity as something other than non-Hispanic
white in the 2010 census (US Census Bureau, 2010). As this patient
population increases, it is critical to recognize the vast clinical presenta-
tions of skin and hair disorders in patients with pigmented skin. The
epidemiology of skin diseases in individuals of color has not been exten-
sively studied (Taylor, 2003). Table 1 provides recent nationally repre-
sentative data from dermatology practice surveys among skin of color
patients (Davis et al., 2012). While acne and unspeciﬁed dermatitis orrie Callender is a Consultant and
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Inc. on behalf of Women's Dermateczema are in the top ﬁve cutaneous diagnoses for all major U.S. racial
and ethnic groups, dyschromia also remains a leading condition
among African Americans and Hispanics (Davis et al., 2012). African
Americans are unique in that alopecia remains a top diagnosis within
this ethnic group (Davis et al., 2012). In particular, there are unique
challenges speciﬁc to treating skin and hair conditions in women
of color. Delays in treatment or misdiagnoses may lead to possible se-
quelae, such as postinﬂammatory hyperpigmentation (PIH), hypertro-
phic scarring, keloid formation, and permanent alopecia. The optimal
treatments for women of color seeking dermatologic care continue to
evolve over time. It is the authors’ aim that a better understanding of
the common skin and hair disorders afﬂicted bywomen of color will ul-
timately lead to more satisfactory outcomes in this patient population.Structure & function of skin of color
The heterogeneity seen among persons of color can be best
explained via the differences in the structure, function, and physiology
of the skin and hair. Literature on ethnic and racial differences in skin
and hair structure, physiology, and function is lacking. Although data
in this area is limited, the literature does offer some insight on the
physiologic and structural variations that exist. It is important to under-
stand these differences since disease presentations are inﬂuenced byologic Society. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Top Ten Dermatologic Conditions Among Caucasian Versus Skin of Color Patients in the United States.⁎
Caucasians African Americans Asian or Paciﬁc Islanders Hispanics or Latinos
Actinic keratosis Acne vulgaris Acne vulgaris Acne vulgaris
Acne vulgaris Unspeciﬁed dermatitis or eczema Unspeciﬁed dermatitis or eczema Unspeciﬁed dermatitis or eczema
Benign neoplasm of the skin Seborrheic dermatitis Benign neoplasm of the skin Psoriasis
Unspeciﬁed dermatitis or eczema Atopic dermatitis Psoriasis Benign neoplasm of the skin
Non-melanoma skin cancer Dyschromia Seborrheic keratosis Viral warts
Seborrheic keratosis Psoriasis Atopic dermatitis Actinic keratosis
Viral warts Alopecia Viral warts Seborrheic keratosis
Psoriasis Keloid scar Urticaria Sebaceous cyst
Rosacea Viral warts Sebaceous cyst Rosacea
Sebaceous cyst Sebaceous cyst Seborrheic dermatitis Dyschromia
⁎ Listed in order of decreasing frequency. Table adapted fromDavis SA, Narahari S, Feldman SR, HuangW, Pichardo-Geisinger RO,McMichael AJ. Top dermatologic conditions in patients
of color: an analysis of nationally representative data. J Drugs Dermatol. 2012;11:466-73.
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monly seen in skin of color (Davis et al., 2012).
Melanocyte biology
It is well known that ethnic and racial differences in skin color are
not due to the number of melanocytes, but rather are due to variations
in the size, number, and aggregation of melanosomes within
keratinocytes and melanocytes (Taylor, 2002). Melanocytes synthesize
melanin in melanosomes which are specialized organelles. Pigmented
melanosomes are transferred from one melanocyte to between 30–35
adjacent keratinocytes in the basal layer. Two types of melanin exist:
eumelanin, a dark brown–black pigment and pheomelanin, a yellow–
reddish pigment. The constitutive levels of pheomelanin and eumelanin
are generally believed to be due to genetics (Taylor, 2002). Eumelanin is
more important in determining the degree of pigmentation than
pheomelanin (Wakamatsu et al., 2006). Lighter melanocytes have
higher pheomelanin content than dark melanocytes (Wakamatsu
et al., 2006). In one study by Wakamatsu et al, Caucasians had the
least amount of eumelanin, Asian Indians had more, and African-
Americans had the highest amount (Wakamatsu et al., 2006). Paracrine
factors secreted from ﬁbroblasts and keratinocytes have also been
shown to play important roles in the regulation of skin pigmentation.
In particular, neuregulin-1 (NRG1) which is highly expressed and se-
creted by ﬁbroblasts derived from Fitzpatrick type VI skin has been
found by Choi et al to play an important role in regulating the constitu-
tive pigmentation of human skin by increasing the proliferation and
pigmentation of melanocytes (Choi et al., 2012). These authors subse-
quently characterized the bioactive motif of NRG1 that is involved in
modulating melanin production in melanocytes by increasing melanin
production (Choi et al., 2012).
Melanosomes also differ among races. In black skin, they are larger
and more active in producing melanin and are packaged, distributed,
and broken down differently than in Caucasian skin (Taylor, 2002).
The number of melanosomes transferred to keratinocytes has also
been shown to be signiﬁcantly higher in skin of African descent versus
white skin as made evident by higher expression of the RAB27A mela-
nosome transport molecule in darkly pigmented melanocytes
(Yoshida-Amano et al., 2012). Protease-activated receptor 2 (PAR-2) is
another contributor to skin pigmentation. This receptor is involved in
various biologic processes including cutaneous pigmentation since its
activation stimulates production of pigment (Babiarz-Magee et al.,
2004). In addition, its expression has been found to be different in
Caucasian skinwhen compared to darker skin. One study demonstrated
that PAR-2 and its activator trypsin are expressed in higher levels in
darker skin andwas also found to have higher cleavage ability in highly
pigmented skin (Babiarz-Magee et al., 2004).
Melanin provides protection from ultraviolet (UV) light. Fitzpatrick
skin phototypes IV–VI are less susceptible to photoaging, which is
most likely due to the photoprotective properties of melanin. Previous
studies have illustrated that the mean UVA transmission through theepidermis is 17.5% in pigmented skin and is 55.5% for Caucasian skin
(Kligman, 1994). The UVB transmission through the epidermis is
5.7% for pigmented skin compared to 29.4% for Caucasian skin
(Kligman, 1994).
Biology of the epidermis and dermis
The structure and function of the epidermis and dermis is similar
among various races and ethnicities, but important differences do exist.
The stratum corneum (SC) serves as the skin’s mechanical barrier
and prevents water loss. Over the years, there has been conﬂicting
data in the literature regarding racial differences in the SC. Early studies
have shown that the stratum corneum of black skin is more compact
than that of white skin (Taylor, 2002). In one study conducted by Chu
and Kollias, corneocyte detachment was more prevalent with age and
was found to be more severe on the dorsal forearm in Caucasian sub-
jects (Chu andKollias, 2011). In addition, corneocyte detachment values
were lower for African-Americans than for Caucasians (Chu and Kollias,
2011). The authors also concluded that the SC appears different
between body sites of different exposures, ages, and persons of different
pigmentation groups, but there are minimal differences in water-
handling properties (Chu and Kollias, 2011). In a study investigating
differences in SC lipids among different ethnicities, the ceramide/
cholesterol ratio was highest in Asians, whites had intermediate values,
and Africans had the lowest values (Jungersted et al., 2010). Another
study showed that East Asian and to some extent Caucasian skin had
low maturation and relatively weak skin barrier (Muizzuddin et al.,
2010). African American skin had low ceramide levels and high protein
cohesion in the uppermost layers of the SC (Muizzuddin et al., 2010).
Transepidermal water loss (TEWL) is deﬁned as the amount of water
vapor loss from the skin, excluding sweat. The difference in TEWL be-
tween different races has yet to be established due to conﬂicting studies.
TEWL has been found to be greater in black skin compared towhite skin
in the majority of studies, but the opposite has also been reported
(Muizzuddin et al., 2010).
The dermis of blacks is thicker andmore compact than that of white
skin (Girardeau-Hubert et al., 2012). The papillary and reticular layers of
the dermis are more distinct, contain larger collagen ﬁber bundles,
and the ﬁber fragments are sparse in whites. In contrast, the dermis of
black skin contains closely stacked, smaller collagen ﬁber bundles
with a surrounding ground substance (Girardeau-Hubert et al., 2012).
Girardeau-Hubert et al showed on histology that African skin had greater
convoluted appearance of the dermal epidermal junction (DEJ) than
Caucasian skin and on immunostaining laminin 332, type IV and VII
collagens, and nidogen proteins at the DEJ were lower in African skin
compared with Caucasian skin (Girardeau-Hubert et al., 2012).
Hair biology
Threemajor categories of hair exist according to ethnic origin: Asian,
Caucasian, and African. Genetics are thought to be responsible for the
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phology. It has been previously noted that the four hair types are helical,
spiral, straight, andwavy (Taylor, 2002). Themajority of blacks have the
spiral hair type (Taylor, 2002). This impart explains why African hair is
more difﬁcult to comb than Caucasian hair. Regarding hair shape, Asian
and Caucasian hair is more cylindrical in contrast to African hair, which
resembles an oval twisted rod that has frequent twists that have
random reversals in direction and pronounced ﬂattening. Asian hair
has the greatest diameter with circular geometry while black hair
shows an elliptic section along the shaft and a high degree of irregularity
in the hair diameter. Caucasian hair is intermediate in diameter and
section shape. Black hair breaks more easily than Caucasian hair due
to the lesser tensile strength and also has lower moisture content
(Ji et al., 2013). A study by Ji et al evaluated the change of integral hair
lipids after UVR in Africans, Asians, and Europeans. The study found
that Asian hair had more integral hair lipids than European and
African hair, but lipid composition overall was similar across the groups
(Ji et al., 2013). African hair in general showed the most hair surface
damage (Ji et al., 2013). The study also revealed that afterUV irradiation,
European and African hair exhibited more damage because they had
less integral hair lipids when compared to Asian hair, which had less
damage (Ji et al., 2013). As measured by high-performance thin-layer
chromatography, integral hair lipids in whole hair follicles are
composed of fatty acid, phytosphingosine, ceramide, cholesterol, cho-
lesterol sulfate, and cholesterol oleate in decreasing order (Lee et al.,
2005). These ﬁndings reiterate the importance of hair care in blacks as
this hair type is naturallymore brittle andmore susceptible to breakage.
Although keratins and their respective amino acids have been reported
to be similar across the three groups, one study showed high variation
in keratin protein expression among Kenyans, Koreans, Caucasians,
African Americans allowing identiﬁcation of individual proﬁles (Laatsch
et al., 2014). On the contrary, differences between these groups were less
marked and relied largely on levels of keratin-associated proteins
(Laatsch et al., 2014). Table 2 summarizes themost established differences
in the structure and function of the skin and hair between Caucasians and
African Americans (Wakamatsu et al., 2006; Yoshida-Amano et al., 2012;
Chu and Kollias, 2011; Jungersted et al., 2010; Girardeau-Hubert et al.,
2012; Ji et al., 2013; Badreshia-Bansal and Taylor, 2009; Weigand et al.,
1974; La Ruche and Cesarini, 1992; Lindelof et al., 1998).
Adult-Female acne
Acne vulgaris is the most commonly reported dermatological com-
plaint among non-Caucasian patients (Halder et al., 1983a; Davis and
Callender, 2010; Callender et al., 2014a). Adult acne is traditionally de-
ﬁned as the presence of acne beyond the age of 25 years and is divided
into persistent and late-onset acne (Callender et al., 2014a). AlthoughTable 2
Comparison of the Structure and Function of Skin and Hair Between Caucasians and African Am
Caucasians African Amer
Stratum corneum thickness Equal Equal
Stratum corneum layers Less More
Stratum corneum lipids Low High
Corneocyte detachment High Low
Ceramide concentration High Low
Melanin content Low High
Melanosomes Small, aggregated Large, dispers
Dermis Thin, less compact Thick, more c
Papillary and reticular layers More distinct Less distinct
Collagen ﬁber bundles Larger Smaller, close
Fiber fragments Sparse Prominent, nu
Hair shaft structure Straight or slightly curved Tightly coiled
Cross-section of hair Slightly less round than Asian hair Oval or ellipti
Tensile strength of hair Higher Lower
⁎ Table modiﬁed from Badreshia-Bansal S, Taylor S. The Structure and Function of Skin of Co
companies. 2009:71-77.once previously regarded as a disease of adolescence, acne vulgaris
may persist from adolescence beyond the age of 25 years (“persistent
acne”) or manifest itself for the ﬁrst time beyond the age of 25 years
(“late-onset adult acne”) (Khunger and Kumar, 2012). Among adult
cases of acne, women tend to be affected more frequently than men;
12-22% of US women have adult acne, compared to 3% of US men
(Goulden et al., 1999). One photographic study found clinical acne to
be highly prevalent in African American (37%), Hispanic/Latinas (32%),
Asian (30%), and Continental Indian (23%) women (Perkins et al.,
2011). Another study reported that adult subjects with acne (mostly
women) comprised the majority of dermatologic ofﬁce visits (61.9%)
while adolescents (aged 15-17 years old) comprised only 36.5% of visits
(Yentzer et al., 2010). In addition, females account for two-thirds of der-
matologic visits for acne and one-third of all ofﬁce visits for acne are by
women over the age of 25 years old (Yentzer et al., 2010).
A recent cross-sectional, web-based survey of 208 women with
adult facial acnewas performed to evaluate the racial differences in clin-
ical characteristics, perceptions, behaviors and psychosocial impact of
acne. In this study, non-Caucasian women experienced substantially
more PIH than Caucasian women (Callender et al., 2014a). In addition,
lesion clearancewas themost important aspect of acne clearing for Cau-
casian women (57.9% vs non-Caucasian 31.7%), whereas clearance of
PIH was most important for many non-Caucasian females (41.6% vs
Caucasian 8.4%) (Callender et al., 2014a). These ﬁndings further empha-
size the importance of developing an individualized, tailored treatment
approach when caring for women of color with acne.
Several previous studies have suggested that adult female acne has a
signiﬁcant negative psychosocial impact in women. A recent cross-
sectional, web-based survey reported the facial acne in adult women
negatively affected their overall health-related quality of life, was asso-
ciated with mild to moderate symptoms of depression and/or anxiety,
and impacted their ability to concentrate on work or school (Tanghetti
et al., 2014). Taken together, these ﬁndings demonstrate the crucial
role dermatologists serve in addressing the symptom burden of acne
in adult women.
Pathogenesis
Themultifactorial pathogenesis of acne vulgaris inwomen of color is
similar to that of Caucasian women and men. The four key components
central to acne pathophysiology include follicular hyperkeratinization,
sebum production, Propionibacterium acnes overgrowth, and inﬂamma-
tion (Fisk et al., 2014). In addition, many previous studies have evaluat-
ed differences in skin biology characteristics between racial ethnic
groups. For example, one small study of 60 women found an overall
higher density of P. acnes in African American subjects (Warrier et al.,
1996). Another study demonstrated that pore size was positivelyericans.⁎
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Fig. 1. Acne in an African American female (Courtesy of Susan C. Taylor, MD, et al; from
Treatments for Skin of Color, copyright Elsevier 2011).
Fig. 3. Pomade acne. Note the closed comedones on the forehead and temples. (Courtesy
of Valerie Callender, MD; from Treatments for Skin of Color by Susan C. Taylor, MD, et al,
copyright Elsevier 2011).
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women (Perkins et al., 2011). However, to date, results from studies
evaluating potential differences in sebaceous gland activity and size
and sebum production between racial groups remain contradictory.
Additional factors such as genetics, diet, cosmetics, tobacco, stress,
medications, and hormonal inﬂuences from estrogens and androgens
also play a role in adult women with acne (Davis and Callender, 2010;
Fisk et al., 2014).
Clinical features
Acne vulgaris in the adult female patient typically presents with
primary lesions on the lower one-third of the face, especially near the
jaw line and chin (Kamangar and Shinkai, 2012) (Fig. 1). Clinical
features that are more frequently encountered in women of color
include dyspigmentation and scarring (Yin and McMichael, 2014). In
one study, these aforementioned events were more common in
African Americans and Hispanic women than all other ethnicities
(Perkins et al., 2011).
PIH is often the presenting complaint among women of color with
darker skin types with acne (Davis and Callender, 2010; Yin and
McMichael, 2014) (Fig. 2). While epidermal lesions may persist for up
to one year, dermal pigmentation may persist for years and may be a
cause of signiﬁcant distress (Yin and McMichael, 2014). In 2013, a
new instrument to measure PIH from acne vulgaris, known as the
postacne hyperpigmentation index (PAHPI), was developed and found
to have good reliability and validity in skin of color subjects (Savory
et al., 2014).
A study performed by Halder et al. (1996) demonstrated histopatho-
logical evidence of marked inﬂammation in all types of acne lesions on
biopsy specimens, including comedones that lacked evidence of inﬂam-
mation clinically. This intensiﬁed level of inﬂammation on histopatholo-
gy in skin of color subjects may account for their increased propensity to
develop PIH. Other complications of acne seen more commonly in
women of color include keloidal scarring and persistent erythema.Fig. 2. Acne and Postinﬂammatory Hyperpigmentation (Courtesy of Valerie Callender,
MD; Callender Dermatology & Cosmetic Center, Glenn Dale, MD).Women of color with acne may also develop distinctive subtypes of
acne secondary to unique cultural practices integral to their ethnic back-
ground. Pomade acne, commonly seen in AfricanAmericans, presents as
closed comedones and papules along the frontal hairline, forehead, and
temples (Davis and Callender, 2010; Yin andMcMichael, 2014) (Fig. 3).
Pomade acne occurs secondary to long-term daily use of oils and thick
emollients used for moisturizing ethnic hair. Acne cosmetica is also
frequently encountered among women of color and presents as come-
dones due to the use of certain cosmetic products that are used to
conceal acne lesions and PIH (Davis and Callender, 2010; Yin and
McMichael, 2014). In addition, steroid acne may be seen in patients
using skin-lightening agents that contain potent topical corticosteroids
in efforts to improve PIH (Callender, 2004).
Treatment
The treatment of acne in women of color is generally similar to that
of Caucasian patients. However, an appropriate understanding of the
sequelae of acne is the key distinguishing characteristic in women of
color. Potential sequelae, such as PIH and keloid scarring, occur more
frequently in individuals with skin of color (Shah and Alexis, 2010).
More severe forms of acne (especially truncal) can be associated with
keloids and may be long lasting or permanent (Shah and Alexis,
2010). Therefore, early and efﬁcacious anti-inﬂammatory agents to
minimize pigmentary abnormalities and keloid scarring must be
balanced with their potential for adverse effects (e.g. avoidance of
potentially irritating topical agents that might further aggravate pre-
existing PIH.) As with all acne patients, one must ﬁrst determine the
predominant type of acne lesion(s) and obtain a history of the patient’s
skin type (normal, oily, dry or combination). An acne/PIH algorithm is
provided in Fig. 4 (Taylor et al., 2011).
Topical retinoids
Topical retinoids, which include adapalene, tretinoin, and tazarotene,
are the mainstay of treatment in mild to moderate acne vulgaris in
women of color. Retinoids are beneﬁcial for women of color as they
treat not only the active acne lesions, but also help ameliorate PIH
(Davis and Callender, 2010). Their mechanism of action includes inhibi-
tion of toll-like receptor (TLR)-2, reduction of the formation of
hyperproliferative keratins, and inhibition of AP-1 pathway, thereby
reducing inﬂammation (Taylor and Summers, 2009). An additional
property of topical retinoids that makes these agents appealing for use
in skin of color patients is their ability to improve PIH by inhibition of
melanosome transfer and facilitating melanin dispersion and removal
(Davis and Callender, 2010; Yin and McMichael, 2014).
Fig. 4. Acne and PIH algorithm (Modiﬁed from Treatments for Skin of Color by Susan C. Taylor, MD, et al, copyright Elsevier 2011).
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includes the potential for inducing a retinoid dermatitis, which is
characterized by xerosis, peeling, and erythema of the skin (Taylor
and Summers, 2009). There are several practical tips that may mitigate
this adverse effect and prevent further worsening of PIH. These include
initiating patients on lower concentrations of topical retinoids, choosing
cream or lotion (over gel), instructing an every-other-day application
regimen with increased frequency as tolerated by the patient, and the
addition of a topical gentle moisturizer (Davis and Callender, 2010;
Yin and McMichael, 2014; Taylor and Summers, 2009).
A study of 171Mexican subjectswith FST III and IVwere evaluated in
a single-center, randomized, double-blinded, placebo-controlled clini-
cal trial evaluating the efﬁcacy and safety of adapalene and tretinoin
(Tirado-Sanchez et al., 2013). The authors found that adapalene 0.3%
gel and tretinoin 0.05% gel were comparable in efﬁcacy in reducing
both inﬂammatory and noninﬂammatory lesions, while tolerance was
better with adapalene 0.1% gel than with adapalene 0.3% and tretinoin
0.05% gel in Mexican subjects.
Grimes and Callender (2006) performed a randomized, double-
blinded, vehicle-controlled study consisting of 74 subjects of darker
racial ethnic groups with acne to assess the efﬁcacy of tazarotene in
the treatment of PIH. In this study, once-daily application of tazarotene
0.1% creamachieved signiﬁcant reduction in overall PIH disease severity
comparedwith vehicle and in the intensity and area of hyperpigmenta-
tion within 18 weeks (Grimes and Callender, 2006).
Topical antimicrobials
Benzoyl peroxide is effective in treating acne due to its suppression
of bacterial proliferation, hyperkeratinization and inﬂammation (Fisket al., 2014). It may be used as monotherapy or in combination with
topical retinoids and antimicrobials. A recent, multicenter, random-
ized, double blind, placebo controlled study (Alexis et al., 2014)
was performed in black subjects with moderate acne to evaluate
the efﬁcacy and safety of adapalene 0.1%/benzoyl peroxide (BPO)
2.5% combination gel. The authors reported that signiﬁcantly more
black subjects had decreased median total, inﬂammatory and nonin-
ﬂammatory lesion counts with adapalene-BPO combination than with
vehicle and signiﬁcant reductions were detected as early as week 1. In
addition, adapalene-BPO was safely tolerated in the black subjects and
no cases of treatment-induced PIH were observed in this study (Alexis
et al., 2014).
Topical antimicrobials such as clindamycin and erythromycin are
used primarily for inﬂammatory acne inwomen of color. Due to the po-
tential development of resistant strains of P. acnes to these agents, they
are often recommended for use in combination with other topical
agents such as BPO or retinoids (Davis and Callender, 2010). A recent,
multi-center, 12-week, double-blinded study consisting of 797 subjects
with moderate to severe acne was performed to assess the efﬁcacy and
cutaneous tolerability of clindamycin phosphate 1.2%/benzoyl peroxide
2.5% gel among FST I through III as compared with FST IV through VI
(Callender, 2012). Treatment success and median reductions in inﬂam-
matory, noninﬂammatory and total lesions at week 12 were compara-
ble between both groups. Subjects with FST IV through VI were not
found to bemore susceptible to cutaneous irritation from this combina-
tion treatment as compared to FST I through III (Callender, 2012).
A recent, randomized, double-blinded, placebo-controlled clinical
trial consisting of 33 subjects with FST IV through VI was performed to
evaluate the efﬁcacy and safety of clindamycin phosphate 1.2% and tre-
tinoin 0.025% gel for the treatment of acne and acne-induced PIH
64 C.N. Lawson et al. / International Journal of Women's Dermatology 1 (2015) 59–75(Callender et al., 2012a). The authors concluded that this combination
gel was safe and effective for skin of color patients with acne.
Azelaic acid
Topical azelaic acid, a dicarboxyclic acid, minimizes both inﬂamma-
tory and noninﬂammatory lesions in acne vulgaris. It is an excellent
treatment option for women of color with acne-induced PIH given its
ability to inhibit tyrosinase (Davis and Callender, 2010; Fisk et al.,
2014). In a pilot study by Kircik, azelaic acid 15% gel applied twice
daily for 16 weeks was found to improve both acne and PIH in subjects
with FST IV through VI (Kircik, 2011).
Dapsone
Topical dapsone is an effective treatment for acne vulgaris due to its
anti-inﬂammatory and antimicrobial properties (Draelos et al., 2007). A
double-blinded, randomized, vehicle-controlled crossover study of 64
subjects, consisting mostly of African Americans, was undertaken to
evaluate the risk of hemolysis in acne patients with glucose-6-
phosphate dehydrogenase deﬁciency (G6PD) who were treated with
dapsone 5% gel vs vehicle gel (Piette et al., 2008). The authors reported
only a 0.32 g/dL decrease in hemoglobin levels from baseline to 2
weeks; however, this was not accompanied by alterations in other lab-
oratory parameters indicative of hemolysis (Piette et al., 2008). The au-
thors concluded that the risk of hemolytic anemia with topical dapsone
5% gel is minimal in patients with G6PD deﬁciency.
Oral agents
Similar to the general population, oral antibiotics are indicated in
women of color for moderate to severe inﬂammatory acne given their
anti-inﬂammatory and anti-microbial properties (Yin and McMichael,
2014). The most common classes of antibiotics used include macrolides
and tetracyclines. Fleischer et al (Fleischer et al., 2006) evaluated an ex-
tended release formulation of minocycline hydrochloride for its safety
and efﬁcacy in a phase 2 dose ﬁnding study and two phase 3 safety
and efﬁcacy trials. The designs were prospective, multicenter, random-
ized, double-blinded, and placebo-controlled and included 1038 partic-
ipants with moderate to severe acne. Study participants received
minocycline 1mg/kg daily or placebo over 12weeks. The number of in-
ﬂammatory lesions was reduced and signiﬁcant improvement was
noted in the Evaluator’s Global Severity Assessment scores (Fleischer
et al., 2006). In both the placebo and treatment groups, acute vestibular
adverse events (AVAEs) were comparable. The authors concluded that
extended release minocycline reduces dose dependent AVAEs, inﬂam-
matory lesions, and improves overall appearance of acne patients.
Recently, a randomized controlled trial (RCT) comparing the efﬁcacy
of oral doxycycline and oral azithromycin in acne treatment showed
that doxycycline is the better treatment option for acne (Ullah et al.,
2014). Subjects with moderate acne received either azithromycin
500mg daily before meals for 4 consecutive days monthly for 3months
or doxycycline 100 mg daily after meals for 3 months and followed up
after 3 months. An excellent response was noted in 3.1% and a good re-
sponsewas observed in 22.8% in the azithromycin group subjects. In the
doxycycline group, 11.4% had excellent and 55.4% had a good response
(Ullah et al., 2014).
Another recent non-inferiority RCT by Tan et al. (2014) compared
the efﬁcacy and safety of oral isotretinoin vs. doxycycline 200 mg plus
adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO) in severe nodu-
lar acne over 20 weeks. The authors found that D+A/BPO showed a fa-
vorable composite efﬁcacy/safety proﬁle compared with isotretinoin
and concluded that this combination can be used as an alternative to
isotretinoin in severe nodular acne (Tan et al., 2014).
Both doxycycline andminocycline have been associatedwith gastro-
intestinal side effects, photosensitivity and photo-onycholysis (Kircik,2010). Three distinct types of cutaneous minocycline-induced pigmen-
tation have been described, which include blue-black pigmentation
conﬁned to sites of scarring or inﬂammation on the face (Type I),
blue-gray circumscribed pigmentation of normal skin on the lower
legs and forearms (Type II), and diffuse muddy brown pigmentation of
normal skin accentuated in sun-exposed areas (Type III) (Mouton
et al., 2004). Minocycline-induced cutaneous hyperpigmentation
ranges in frequency from 2.4% to 14.8% in several longitudinal studies
(Soung et al., 2007). In addition, minocycline has been associated with
the development of autoantibodies, including anti-nuclear antibody
(ANA), anti-neutrophil cytoplasmic antibody (ANCA), and anti-
phospholipid antibodies with or without associated clinical symptoms
(Kircik, 2010). Of note, minocycline has been recently associated with
drug-induced lupus, with the majority of cases (84%) occurring in
young women taking minocycline for acne (Kircik, 2010). Therefore,
in women of color, one must carefully weigh the beneﬁts and risks of
these agents, paying particular attention to the risk of photosensitivity,
gastrointestinal concerns, skin hyperpigmentation, and autoimmune
and hypersensitivity syndromes (Davis and Callender, 2010).
Any adult female patient with difﬁcult-to-treat acne should be eval-
uated for a possible underlying endocrine disorder, especially
hyperandrogenism. Polycystic ovarian syndrome (PCOS) is the most
common cause of hyperandrogenism and cutaneous signs of PCOS in-
clude acne, hirsutism, androgenetic alopecia, seborrhea and acanthosis
nigricans (Kamangar and Shinkai, 2012). One recent study supports
the concept that women often report worsening of acne prior to the
onset of their menses, with 65% of all participants reporting
perimenstrual acne ﬂare (Geller et al., 2014). The subset of women
with acne exacerbations related to their menstrual cycle may be the
best candidates to beneﬁt from hormonal therapy such as oral contra-
ceptive pills.
Isotretinoin, an oral retinoid approved by the US Food and Drug Ad-
ministration, is the treatment of choice for severe nodulocystic acne in
skin of color (Davis and Callender, 2010). Special attention and educa-
tion is mandatory for women of childbearing age given its serious sys-
temic toxicities, which include teratogenicity (pregnancy category X),
dyslipidemia, pancreatitis, hepatotoxicity, and pseudotumor cerebri
(Davis and Callender, 2010; Yin and McMichael, 2014). An interesting
study done by Kelly and Sampson (1987) was performed to evaluate
the response of African American patients with recalcitrant
nodulocystic acne to isotretinoin treatment. Of the 10 subjects studied,
the author reported an early onsetﬂare in areas of the face thatwere ini-
tially devoid of lesions prior to treatment. In addition, the author also re-
ported an improvement in PIH at the completion of the study (Kelly and
Sampson, 1987). The subjects in this studywere also noted to develop a
temporary ashen or grayish facial hue between the second and eighth
week of therapy, which was likely attributed to the drying and
desquamative effects of isotretinoin. In order to avoid non-compliance
and treatment failures, it is critical to educate patients with darker
skin prior to initiation of isotretinoin that dyschromia may occur.
Cosmetic therapies
Atrophic acne scarring is another potential sequela of acne in skin of
color patients that presents a therapeutic challenge (Shah and Alexis,
2010). A study consisting of 30 subjects with atrophic ice pick scars
was performed to assess the efﬁcacy and safety of the chemical recon-
struction of skin scars (CROSS) technique in FST IV and V using high
strength trichloroacetic acid (TCA) focally into the depth of the scar to
induce collagen production (Khunger et al., 2011). The subjects were
initially primed for twoweeks before the procedure with hydroquinone
4% cream in the morning and tretinoin 0.025% cream in the night. Focal
application of 100% TCAwith awooden toothpick in each individual scar
at two weekly intervals for four sessions resulted in excellent improve-
ment in 73.3% of subjects. Transient hypopigmentationwas observed in
one subject and hyperpigmentation in two subjects. At three-month
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changes or scarring were noted. However, given the increased risk of
dyschromias and keloid scarring in skin of color patients, the current au-
thors emphasize that concentrations of TCA greater than 35% should be
usedwith extreme caution in such patients as higher concentrations are
thought to be melanotoxic.
Laser technology can also be an effective adjunct therapy in theman-
agement of acne in women of color. Gold performed an evaluation on
ﬁve subjects with using a novel superﬁcial and deep carbon dioxide
(CO2) fractional laser in FST IV and V with acne scarring (Gold, 2012).
Although this study included a small sample size, all subjects had clini-
cally signiﬁcant improvement in their skin and no reports of PIH were
noted. A recent single-center prospective study assessed the clinical
efﬁcacy and safety of the 1450-nm diode laser for the treatment of
acne scarring in patients with FST IV to VI (Semchyshyn et al., 2013).
While the authors found the nonablative 1450-nm diode laser to be
effective in improving the appearance of atrophic acne scars in these
subjects, PIH was noted in 56% of the subjects (Semchyshyn et al.,
2013). Therefore, while lasers may be beneﬁcial in treating acne-
related scarring, similar to most other surgical procedures, caution
must be utilized with use of lasers in women of color given the risks
of postinﬂammatory hyper- and hypopigmentation and scarring.
Recently, the efﬁcacy and safety of polymethylmethacrylate
(PMMA) suspended in bovine collagenwas evaluated for the correction
of atrophic facial acne scars in a study by Karnik et al. (2014). The study
was amulticenter, double blind, RCT that included 147participantswith
more than 20% reporting Fitzpatrick skin types V and VI. Those with at
least 4 moderate to severe rolling, atrophic scars were included.
Subjects were randomized to PMMA-collagen or saline injections
and underwent 2 injection sessions. Follow up was for 6 months. Scar
severity was assessed using the Acne Scar Rating Scale (ASRS). The
study included 1288 scars with 863 in the PMMA-collagen group and
425 in the control group. Successful results were achieved in 64% of
the PMMA-collagen group compared with 33% of the control group.
The study found no signiﬁcant differences in efﬁcacy or safety for darker
skin types. Upon assessment of adverse events (particularly those
concerning for darker skin types which include hypertrophic scarring,
hypopigmentation, or hyperpigmentation), none were seen. Overall,
the authors concluded that PMMA-collagen is an effective treatment
for facial atrophic acne scars and maintains an excellent safety proﬁle
(Karnik et al., 2014). With regards to darker skin types, the authors
highlight that the complete lack of dyspigmentation along with excel-
lent treatment outcomes makes PMMA-collagen a great treatment
modality for darker skin types (Karnik et al., 2014).
A summary of clinical studies on acne in skin of color is provided in
Table 3.
Melasma
Melasma is an acquired hypermelanosis of the skin characterized by
hyperpigmented macules and patches distributed symmetrically on
sun-exposed areas of the body, particularly on the face. Most cases
occur in women of reproductive age with darker skin tones (Fitzpatrick
skin type IV–VI) living in areas of intense ultraviolet (UV) radiation, but
people of all ages, races, and skin colors may be affected. Its pathogene-
sis is not completely understood. The majority of cases have been asso-
ciated with identiﬁable risk factors such as genetic predisposition,
ultraviolet (UV) radiation and hormonal inﬂuences including oral
contraceptives and pregnancy, anti-seizure and phototoxic medica-
tions, and thyroid disease (Grimes, 1995; Sheth and Pandya, 2011a).
In fair skinned individuals, the pigmentation may reduce or resolve
completely after parturition, whereas, it may persist in women with
darker skin.
Based on the distribution of the facial lesions, melasma is classiﬁed
into malar, centrofacial, mandibular and combination patterns of these
(Figs. 5-6). In the Indian subcontinent, a majority of patients show amalar distribution compared with disease pattern in Western popula-
tion where centrofacial pattern predominates (Sheth and Pandya,
2011a; Sardesai et al., 2013). Based on Wood's lamp examination, it
has been classiﬁed as epidermal, dermal, mixed, and indeterminate
variants in Type IV-VI skin (Grimes, 1995; Sheth and Pandya, 2011a).
While a Wood’s lamp examination was previously thought to precisely
predict epidermal versus dermal pigment deposition, recent studies
have shown that dermal melanin deposition is common and may be
underrecognized given that many patients often exhibit a mixed
pattern (Grimes, 1995; Sheth and Pandya, 2011a; Sardesai et al., 2013).
Medical management
A broad-spectrum UVA- and UVB-protective sunscreen with a sun
protection factor (SPF) of at least 30 along with a physical blocker,
such as titanium dioxide or zinc oxide, should be applied daily in pa-
tients withmelasma. In addition to protection fromultraviolet radiation
(UVR), visible light protection is also warranted as it also impacts
pigmentation. Recently, it has been shown that short wavelengths of
visible light (415 nm) can induce prolonged hyperpigmentation in com-
parison to long wavelengths (630 nm), which do not impact pigmenta-
tion in healthy volunteers (Boukari et al., 2015). Boukari et al. (2015)
recently conducted a RCT in real-life settings during the spring and
summer evaluating the protective properties against melasma relapses
of a sunscreen protecting against UVA/UVB and the shorterwavelengths
of visible light compared to a sunscreen with UVA/UVB protection but
without visible light protection. The study included 40 melasma
patients representing FST III –V. Subjects were randomized to receive
either Formula A (tinted and contained iron oxides) or Formula B,
which were initially analyzed with photospectrometric analysis to
assess the absorption potential of visible light. Patients applied 1 dose
of the respective product twice daily and an additional dose every
2 hours, and 30 minutes before exposure to daylight. Patients were
instructed to apply 1 teaspoon of sunscreen to the face. Themain clinical
assessmentwas theMelasmaArea and Severity Index (MASI) score. The
median increase of the MASI score from baseline to month 6 was more
important with Formula B than with Formula A. Also, the tinted sun-
screen only provided a partial protection in the targeted visible wave-
lengths according to the photospectrometric analysis. Given their
results, the authors emphasize the impact that visible light has on
melasma pathogenesis. Thus, they note the importance of developing
more effective ﬁlters that protect against these wavelengths (Boukari
et al., 2015). Additional sun protective measures, such as limited time
outdoors, use of protective clothing and hats, and sun avoidance when
possible are also essential to the treatment of melasma.
Currently, there is no single universally effective therapeutic agent for
the treatment of melasma as the condition is recurrent and challenging.
Conventional treatment of melasma includes elimination of any possible
causative factors coupled with the use of a broad-spectrum sunscreen
and skin lightening agents such as topical retinoids, hydroquinone,
kojic acid, azelaic acid, deoxyarbutin, or ascorbic acid as monotherapy
or in combination formulations using the modiﬁed Kligman’s formula.
Triple combination (TC) therapy, comprised of hydroquinone, a
retinoid, and a ﬂuorinated corticosteroid, is considered to be a highly
effective and safe treatment for melasma in skin of color (Rivas and
Pandya, 2013). One of the most successful TC therapy regimens consists
of a ﬁxed combination of 4% hydroquinone, 0.05% tretinoin and 0.01%
ﬂuocinolone acetonide (Sheth and Pandya, 2011b). Taylor et al. (2003)
conducted one of the initial studies demonstrating the high efﬁcacy of
this TC by comparing nightly use of TC cream with nightly use of three
dual-combination creams (4% hydroquinone plus 0.05% tretinoin, 0.05%
plus 0.01% ﬂuocinolone acetonide, and 4% hydroquinone plus 0.01%
ﬂuocinolone acetonide). After 8weeks, complete clearancewas achieved
in 26.1% of subjects treated with TC cream in comparison with 9.5%
of subjects using hydroquinone plus tretinoin, 1.9% of subjects using tre-
tinoin plus ﬂuocinolone, and 2.5% of subjects using hydroquinone plus
Table 3
Review of Acne in Skin of Color.
Authors Study Design Total # of
Subjects (N)
Summary of Results Level of
Evidence
Strength of
Recommendation
Tirado-Sanchez
et al. (2013)
Single-center, randomized,
double-blinded placebo-
controlled study
171 subjects
(F=94; M=77)
At 90 days of treatment, the efﬁcacy rates of tretinoin 0.05% gel,
adapalene 0.3% gel and adapalene 0.1% gel were 80%, 70%, and
59% respectively.
Tolerance was better with adapalene 0.1% gel than with
adapalene 0.3% and tretinoin 0.05% gel (P = 0.001).
I A
Grimes and
Callender (2006)
Multicenter, randomized,
double-blinded, vehicle-
controlled study
74 subjects
(F=65; M=9)
Once-daily tazarotene 0.1% cream was signiﬁcantly more
effective than vehicle in lessening PIH overall (P = 0.010), and
in reducing the intensity (P = 0.044) and area of
hyperpigmented lesions (P = 0.026) within 18 weeks.
I A
Alexis et al.
(2014)
Multicenter, randomized,
double-blinded, placebo-
controlled study
238 subjects
(F=166; M=72)
After 12 weeks, signiﬁcant reductions in total, inﬂammatory and
noninﬂammatory lesion counts were observed with adapalene
0.1%/BPO 2.5% gel than vehicle.
After 12 weeks, most subjects reported no dryness (N89.9%), no
erythema (N90.9%), no scaling (N96.0%), or no stinging/burning
(N94.9) with adapalene-BPO treatment.
I A
Callender (2012) Multicenter, randomized,
double-blinded, vehicle-
controlled study
797 subjects
(F=408; M=389)
Treatment success with clindamycin phosphate 1.2%/BPO 2.5%
gel was comparable between FST I-III and FST IV-VI at week 12.
Patients with FST IV-VI were not found to bemore susceptible to
cutaneous irritation than patients with FST I-III.
I A
Callender et al.
(2012a)
Multicenter, randomized,
double-blinded, placebo-
controlled study
33 subjects
(F=26; M=7)
Clindamycin phosphate 1.2%/tretinoin 0.025% gel-treated
patients had a greater decrease in inﬂammatory lesion counts
from baseline than vehicle group at week 12 (P = 0.05).
I B
Kircik (2011) Single-center, open-label
pilot study
20 subjects
(F=15; M=5)
At week 16, azelaic acid 15% gel applied twice daily resulted
in 92% of subjects with at least a one-point improvement in
IGA for acne and 100% of subjects had at least a 2-point
improvement in IGA for PIH.
II-iii B
Piette et al. (2008) Multicenter, randomized,
double-blinded, vehicle-
controlled crossover study
64 subjects
(F=35; M=29)
Subjects with glucose-6-phosphate dehydrogenase
deﬁciency (G6PD) treated with dapsone 5% gel had only a
0.32 g/dL decrease in hemoglobin levels from baseline to 2
weeks; however, no changes were noted in reticulocytes,
haptoglobin, bilirubin or lactate dehydrogenase levels.
I A
Fleischer et al.
(2006)
Multicenter, randomized,
double-blinded, placebo-
controlled study
1038 subjects
(F=449; M=589)
An extended release formulation of minocycline
hydrochloride was evaluated in subjects with moderate to
severe acne in a phase 2 dose ﬁnding study and two phase 3
safety and efﬁcacy trials. Study participants received
minocycline 1 mg/kg daily or placebo over 12 weeks.
The number of inﬂammatory lesions was reduced and
signiﬁcant improvement was noted in the Evaluator’s Global
Severity Assessment scores. In both the placebo and treatment
groups, acute vestibular adverse events (AVAEs) were
comparable. The authors concluded that extended release
minocycline reduces dose dependent AVAEs, inﬂammatory
lesions, and improves overall appearance of acne patients.
I A
Ullah et al.
(2014)
Single-center, randomized
controlled study
386 subjects
(F=215; M=171)
Subjects with moderate acne received either azithromycin
500 mg daily before meals for 4 consecutive days monthly for
3 months or doxycycline 100 mg daily after meals for 3 months
and followed up after 3 months. An excellent response was
noted in 3.1% and a good response was observed in 22.8% in the
azithromycin group. In the doxycycline group, 11.4% had
excellent and 55.4% had a good response. The authors concluded
that doxycycline is the better treatment option for acne.
I A
Tan et al. (2014) Multicenter, randomized,
controlled, noninferiority,
investigator-blinded study
266 subjects
(F=39; M=227)
The efﬁcacy and safety of oral isotretinoin versus doxycycline
200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel
(D+A/BPO) was compared in subjects with severe nodular
acne over 20 weeks. The authors found that D+A/BPO
showed a favorable composite efﬁcacy/safety proﬁle
compared with isotretinoin and concluded that this
combination can be used as an alternative to isotretinoin in
severe nodular acne.
I A
Kelly and
Sampson
(1987)
Case series 10 subjects 10 African American subjects with recalcitrant nodulocystic acne
treated with isotretinoin developed an early onset ﬂare of
nodulocystic lesions at sites initially devoid of acne lesions at
weeks 2-4.
At completion of the study, an improvement in PIH was noted.
Betweenweeks 2-8,most subjects developed a reversible ashen or
grayish facial hue (due to the drying and desquamative effects of
isotretinoin).
II-iii B
Khunger et al.
(2011)
Case series 30 subjects
(F=20; M=10)
Subjects with FST IV and V with atrophic ice pick acne scars
were primed for 2 weeks (with hydroquinone 4% cream in
the morning and tretinoin 0.025% cream at night) prior to
receiving focal application of 100% trichloroacetic acid (TCA)
to each scar at 2-week intervals for 4 sessions.
Excellent improvement was seen in 73.3% of subjects, while
20% showed good improvement and 6.7% had fair results.
II-iii C
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Table 3 (continued)
Authors Study Design Total # of
Subjects (N)
Summary of Results Level of
Evidence
Strength of
Recommendation
Transient hypopigmentation was observed in 1 patient and
hyperpigmentation was observed in 2 patients. No
signiﬁcant prolonged pigmentary changes or scarring were
noted at 3 month follow-up.
Gold (2012) Case series 5 subjects
(F=3; M=2)
Subjects with FST IV and V treated with a novel superﬁcial
and deep AcuPulse MultiMode carbon dioxide (CO2)
fractional laser had clinically signiﬁcant improvement in
acne and no reports of PIH were noted.
II-iii C
Semchyshyn et al.
(2013)
Case series 20 subjects Subjects with FST IV through VI treated with a nonablative
450-nm diode laser found it to be effective in improving the
appearance of atrophic acne scars, however, PIH was common
in 56% of subjects.
II-iii C
Karnik et al.
(2014)
Multicenter, randomized,
double-blinded, controlled
study
147 subjects
(F= 90; M =57)
Subjects with at least 4 moderate to severe rolling, atrophic
scars randomly received polymethylmethacrylate (PMMA)
suspended in bovine collagen (PMMA-collagen) or saline
injections. Subjects underwent up to 2 injection sessions and
were followed up for 6 months. Success was achieved by 64%
of those treated with PMMA-collagen compared with 33% of
control subjects (P = .0005). The treatment showed excellent
safety with generally mild, reversible adverse events. No
signiﬁcant differences in efﬁcacy or safety were noted
between genders, for darker skin types, or in older age groups.
I B
* In accordance with the US Preventive Services Task Force levels of evidence for grading clinical trials (Sheth and Pandya, 2011b), (see Appendix A).
Abbreviations: F, female; M, male; BPO, benzoyl peroxide; PIH, postinﬂammatory hyperpigmentation; FST, Fitzpatrick skin type; IGA, investigator global assessment.
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clearance was achieved in 77% of patients on the TC therapy versus a
maximum of 46.8% in subjects using the dual combination preparations.
Adverse effects such as erythema, peeling, irritation and dryness were
highest in the combination regimens containing tretinoin, however,
these side effects were transient and mild (Taylor et al., 2003). Several
additional publications have subsequently demonstrated the safety and
efﬁcacy of this TC cream, particularly in darker-skinned racial ethnic
groups (Torok, 2006; Torok et al., 2005a; Chan et al., 2008).
Given the relapsing nature of melasma, maintenance regimens are
often necessary to sustain efﬁcacy after initial stabilization. A study
conducted by Arellano et al. (2012) was performed to determine the
maintenance therapy for patients in whom TC therapy had shown to
be effective. The authors found that the twice-weekly TC therapy
group had a lower relapse rate compared with the tapering regimen
group (3 times weekly for the ﬁrst month, twice weekly for the second
month and once weekly for the fourth month) (Arellano et al., 2012).
Torok et al. (2005b) conducted a 12-month extension of an 8-week
multicenter RCT consisting of 327 subjects evaluating the safety and
efﬁcacy of once daily TC cream in facial melasma. The study concluded
that TC cream had a favorable safety proﬁle and when appliedFig. 5.Melasma, malar variant (Courtesy of Jean Bolognia, MD; from Dermatology, copyright
Elsevier, 3rd ed., 2012).intermittently over a long time period is tolerable, safe, and effective
for moderate to severe facial melasma (Torok et al., 2005b).
Other combination creams have also been studied and show
promising results. In a randomized study conducted by Lim, 40 Chinese
female subjects were treated with 2% kojic acid in a gel containing 10%
glycolic acid and 2% hydroquinone (Lim, 1999). The gel was applied to
one-half of the face twice daily and compared with a gel containing
only 10% glycolic acid and 2% hydroquinone applied to the other half
of the face twice daily for 12 weeks. The authors found that in 60% of
the subjects in the kojic acid group, more than 50% of melasma lesions
had cleared versus 47.5% of subjects in the 10% glycolic acid and 2%
hydroquinone group (Lim, 1999). More recently, a hydroquinone-free,
multimodal complex skin lightening agent has been developed to
address dyschromias such as melasma. This agent acts via targeting
multiple pathways in melanin synthesis including reduction in melano-
cyte activation,melanin synthesis,melanin transfer to keratinocytes, and
epidermal melanin (Makino et al., 2013). Grimes (2014) presented a
case report of six female subjects with Fitzpatrick skin types IV - V with
moderate epidermal facial melasma treated with a hydroquinone-free,
multimodality skin brightener. Patients applied the agent twice daily
and were evaluated at 4, 8, and 12 weeks. The Investigator OverallFig. 6. Melasma, centrofacial variant with sparing of the philtrum (Courtesy of Jean
Bolognia, MD; from Dermatology, copyright Elsevier, 3rd ed., 2012).
Table 4
Levels of evidence and strength of recommendations for various peeling agents in ethnic
skin (Sarkar et al., 2012).
Peeling agent Level of evidence Strength of recommendation
Glycolic acid peel II-i A
Lactic acid peel II-iii B
Salicylic acid peel II-iii B
Trichloroacetic acid peel II-iii B
Jessner’s solution II-iii B
Phytic acid peel III C
Pyruvic acid peel III C
* In accordance with the US Preventive Services Task Force levels of evidence for grading
clinical trials (Sheth and Pandya, 2011b), (see Appendix A).
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scores improved by an average 38%. In addition, 100% of the
participants showed at week 12 at least a 25% increase in Global
Improvement. The skin brightener was well tolerated without pruritus,
erythema, edema, scaling, or burning/stinging reported (Grimes, 2014).
In summary, it is recommended that patients with mild melasma
use non-phenolic therapy such as azelaic acid (AZ), arbutin, kojic acid,
tretinoin, adapalene and glycolic acid or any combination of these or
4% hydroquinone as monotherapy. For moderate to severe melasma,
TC therapy is the gold standard. These agents are often used in concur-
rence with other physical therapies.Chemical peels
A wide variety of agents are available for chemical peels, however,
the choice is rather limited while treating a patient with Fitzpatrick
skin type IV - VI. Use of medium-depth peels is advised with caution
and deep phenol peels are avoided owing to risk of scarring and
prolonged hyperpigmentation (Sarkar et al., 2012; Salam et al., 2013).
Among the superﬁcial peels, 20–30% salicylic acid in ethanol is widely
considered to be the safest peel in the ethnic skin population (Salam
et al., 2013). Based on current available evidence, glycolic acid peels
(20-70%) every 4-6 weeks are a useful adjunctive therapy in refractory
cases of epidermal melasma (Sheth and Pandya, 2011b; Sarkar et al.,
2012; Salam et al., 2013). It is the most widely utilized peeling agent
in skin of color and has proven safety as well as efﬁcacy. Superﬁcial
trichloroacetic acid (TCA) peels (10-25%) should be used with caution
in darker skin types due to the risk of pigment dyschromias andTable 5
Levels of evidence and strength of recommendations for lasers and light based devices for trea
Type of laser Le
Q switched lasers Q switched Ruby (Jang et al., 2011; Hilton et al., 2013) II-
Q switched Alexandrite (Fabi et al., 2014; Rusciani et al., 2005) II-
Q switched Nd:Yag-“laser toning/laser facial” (Wattanakrai
et al., 2010; Bansal et al., 2012; Sim et al., 2014)
I
Light devices IPL (Zaleski et al., 2012) II-
Fractional Ablative lasers Erbium:YAG (Attwa et al., 2014; Manaloto and Alster, 1999) II-
CO2 (Jalaly et al., 2014; Neeley et al., 2010) II-
Vascular lasers PDL (Passeron et al., 2011) II-
Fractional lasers
Non- ablative
(Wind et al., 2010)
Non-ablative 1,550 nm fractional laser therapy I
1,927-nm thulium ﬁber laser (Polder and Bruce, 2012) II-
* In accordance with the US Preventive Services Task Force levels of evidence for grading clinic
Abbreviations: IPL, intense pulsed light; PDL, pulsed dye laser; PIH, postinﬂammatory hyperpigscarring. The most common sequela with the use of chemical peels for
melasma in ethnic skin is PIH,which can either occur between the treat-
ment sessions or after stopping treatment. Pre-peel priming with
hydroquinone and tretinoin for 2-4 weeks enhances the effect of the
peeling agent apart from decreasing the PIH, with hydroquinone con-
sidered superior to tretinoin as a priming agent (Nanda et al., 2004).
Recommendations of chemical peels for melasma in skin of color are
provided in Table 4.
Light and laser therapy (Arora et al., 2012; Sardana and Garg, 2014)
Published data or recommendations on the safety and effectiveness
of lasers in Fitzpatrick skin types V – VI are limited by complications of
post procedure hyper- or hypopigmentation. Several of the lasers
utilized as options for the treatment of melasma, including the
pigment-speciﬁc lasers (Q-switched, long-pulsed lasers and intense
pulsed light or IPL), ablative lasers (Er:YAG) and fractional lasers have
had conﬂicting results and are anecdotal. Most of the studies reported
in Asians have been performed on Fitzpatrick skin types III – IV and
demonstrate that lasers may cause worsening of the disease, minimally
improve it, or produce unwanted PIH (Jang et al., 2011).
A recent 2013 evidence-based review of treatments for melasma
demonstrated overall that laser and light therapy yields varied results
and that relapse is a frequent occurrence after treatment (Rivas and
Pandya, 2013). While IPL therapy has been shown to be effective in
improving melasma, it is characterized by a high relapse rate (Wang
et al., 2004). QS-Nd:YAG lasers are associated with an increased risk of
rebound hyperpigmentation and a very high rate of relapse following
treatment (Wattanakrai et al., 2012). In general, laser and light
therapies are considered third-line agents for the treatment ofmelasma
and further research is needed. Most physicians recommend priming
the patient’s skin with triple combination prior to laser therapy
and continue to use this regimen after treatment sessions. Low ﬂuence
and low treatment density non-ablative fractional lasers and Q-switched
1064 nm can be considered as third-line treatment for patients
who have not improved sufﬁciently after 3–6 months of topical
treatment (Table 5).
Alopecia
Hair care practices
Hair and scalp disorders in women of African descent are particu-
larly challenging, partially due to a paucity of research into theting melasma in skin of color.
vel of evidence Strength of
recommendation
Side effects and complications
iii C PIH and recurrence of melasma
Post operative discomfort
iii C PIH
B Erythema, burning, swelling, whitening
of hair Spotty depigmentation
Rebound hyperpigmentation
Recurrence of melasma
iii C Erythema
Pain
PIH
iii C PIH
iii C PIH
Rebound melasma
iii C PIH
C Erythema, burning sensation, edema,
pain and PIH
iii C Moderate erythema and mild edema
al trials (Sheth and Pandya, 2011b), (see Appendix A).
mentation.
Fig. 8. Chemical relaxer application to hair (Courtesy of Susan C. Taylor, MD, et al; from
Treatments for Skin of Color, copyright Elsevier 2011).
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standing of the basic hair care practices in this patient population.
Below we discuss some of the more common grooming practices
that could signiﬁcantly impact the clinical presentation of hair and
scalp disorders, and compliance with treatment regimens.
Several hairstyles common in people of African descent result in
tension at the root of the hair follicles. These include cornrows (formed
by braiding the hair tightly into individual sections) and dreadlocks
(a type of styling allows the hair to knot into individual twistlike struc-
tures) (Ogunleye et al., 2014). In either of these styles, human or
synthetic hair may be added for increased length and volume
(Callender et al., 2004). Hair weaving is another common hairstyle,
where the hair is cornrowed and additional hair is sewn or glued to
the cornrows. These methods of styling have all been associated with
traction alopecia or marginal scalp hair loss (Grimes, 2000).
Straightening of the hair has traditionally been the style of choice in
black women, as it is thought to increase styling options and manage-
ability of the hair (Ogunleye et al., 2014; Callender, 2002). This can be
achieved via thermal straightening or chemical straightening. Thermal
straightening, also known as hot combing or pressing, involves tempo-
rarily rearranging hydrogen bonds within the hair shafts (Callender
et al., 2004). The hair is coated with a lubricating oil and then combed
with a hot metal comb heated to 300 to 500°F (LoPresti et al., 1968).
An alternative to the hot comb is the ﬂat iron. Here, the hair is placed
between 2 hot smooth, ceramic plates with temperatures ranging from
180 to 450°F (Fig. 7).
Chemical relaxers produce permanent hair straightening by
rearranging disulﬁde bonds within the shaft; using sodium hydroxide
in lye relaxers, and guanidine hydroxide in no-lye relaxers (Fig. 8).
These often result in irritant contact dermatitis, trichorrhexis nodosa,
and fragile, easily damaged hair (Swee et al., 2000). A newer method
of hair straightening, known as the Brazilian keratin treatment, is a pro-
cess in which a liquid keratin solution is sealed into the hair using a ﬂat
iron. Formaldehyde, the preservative used in this process, can be a
signiﬁcant health concern to both stylists and clients.
In terms of hair cleansing, African American women tend to sham-
poo less frequently than other ethnicities, approximately once every 1
to 2 weeks (Hall et al., 2013). This is partially due to lower levels of
sebum on the hair shaft, with resulting dryness and breakage if
shampooed too frequently. Also, the hairstyles described above are
time consuming and costly, and so the hair is washed infrequently in
an attempt to maintain these hairstyles for longer periods of time
(Callender, 2002; McMichael, 2003).Fig. 7. (Left to right) Electric curling iron, hot comb and ceramic ﬂat iron (Courtesy of
Valerie Callender, MD; from Treatments for Skin of Color by Susan C. Taylor, MD, et al, copy-
right Elsevier 2011).Traction Alopecia
Traction alopecia (TA) is a form of alopecia loss caused by repetitive
or prolonged tension to the hair. Although early disease is non-scarring,
longstanding TA can lead to permanent hair loss. TA is most frequently
reported in individuals of African descent (Khumalo et al., 2007a,b) and
is closely linked to the unique hair grooming practices and increased
susceptibility of the hair follicles in this patient population (Mulinari-
Brenner and Bregfeld, 2001).
The earliest clinical sign of traction on the scalp is perifollicular
erythema, whichmay progress to follicular papules and pustules. Even-
tually, yellow-white cylinders, known as peri-pilar casts, encircle the
hair shaft at sites of traction (Samrao et al., 2011; Rollins, 1961; Fox
et al., 2007; Tosti et al., 2010). Subsequently, clinically apparent alopecia
develops, with decreased follicular markings in late stage disease
(Samrao et al., 2011).
TA often affects the frontal and temporal scalp, as well as anterior
and superior to the ears (Fig. 9). Patients usually report a history of
tight braids, weaves, cornrows, ponytails, chignons or religious head
coverings. There is a signiﬁcantly higher risk of developing TA when
traction is applied to chemically treated hair, such as relaxers and
dyes; but does not appear to be affected by the frequency of relaxer
application (Khumalo et al., 2007a, 2008). The presence of retained
hairs along the frontal and/or temporal hairline, termed the “fringe
sign,” is a common ﬁnding in patients with TA of the marginal hairline,
and can help in making a clinical diagnosis of TA (Samrao et al., 2011).
As the early stage of TA is reversible, it is very important that the
public be educated on the increased risk of TA in patients with symp-
tomatic traction an combined hairstyles, such as the tight braiding of
relaxed hair. It has been suggested that to inﬂuence the practice of atFig. 9. Traction alopecia (Courtesy of Valerie Callender, MD; from Treatments for Skin of
Color by Susan C. Taylor, MD, et al, copyright Elsevier 2011).
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messages like "tolerate pain from a hairstyle and risk hair loss" and
"no braids or weaves on relaxed hair" (Mirmirani and Khumalo, 2014).
An unusual variant of TA resulting from the use ofwefted hair exten-
sions, termed the “horseshoe” pattern, has been reported (Ahdout and
Mirmirani, 2012).Wefts consist ofmultiple strands of hair held together
by a band of ﬁne threads, and are attached directly to the hairline by
being sewn, bonded, glued, or clipped. TA has also been reported in
Hispanic women with long hair who wear tight ponytails, and in
Japanese women and ballerinas who frequently wear their hair in a
tight bun. In these cases, the hair loss may be conﬁned to the occipital
or temporal scalp (Trueb, 1995; Samrao et al., 2010a).
In patients who give a remote or unclear history of tight hairstyles,
the clinical differential diagnosis includes androgenetic alopecia, telogen
efﬂuvium, trichotillomania and central centrifugal cicatricial alopecia.
When TA is localized to the marginal hairline, frontal ﬁbrosing alopecia
and the ophiasis pattern of alopecia areata should be considered
(Heath and Taylor, 2012).
Treatment options for TA depend on duration of the disease process.
Firstly, patients should be advised that TA may lead to permanent pro-
gressive alopecia (James et al., 2007). In early disease, the hairstyle
should be loosened, and chemicals, heat and combined hairstyles
should be avoided. Intralesional corticosteroids directed at the periph-
ery of hair loss, suppress peri-follicular inﬂammation (Callender et al.,
2004). Oral or topical antibiotics may also be used in early disease for
their anti-inﬂammatory effect (Callender et al., 2004). Topical minoxidil
may also be considered in conjunctionwith intralesional corticosteroids
(Khumalo and Ngwanya, 2007). In longstanding disease, dermal
scarring leads to permanent alopecia. In these advanced cases, surgical
options such as hair transplantation may be considered (Callender
et al., 2004; Ozcelik, 2005).
Acquired Trichorrhexis Nodosa
Trichorrhexis nodosa (TN), a hair shaft disorder, is characterized by
fragility and nodes along the shaft. The hair appears lusterless and dry
and patients may complain of “whitish spots” along the hair (Martin
and Sugathan, 2011) (Fig. 10). The underlying pathogenic mechanism
seems to be the loss of cuticle cells along the shaft. As a result, the
cortical ﬁbers lose their protection, and split longitudinally into
numerous small ﬁbers. On microscopic examination, there is cuticular
cell disruption and fraying and breaking of the cortical ﬁbers, with the
resulting appearance likened to two paint brushes crushed against
each other, hence the description “paint brush fracture” (Martínez de
Lagrán et al., 2009; Rudnicka et al., 2013; Miyamoto et al., 2009).
TNmay be congenital or acquired. Acquired TN results from repeated
trauma to the hair (Khumalo et al., 2007a,b, 2008; Mulinari-Brenner andFig. 10. Trichorrhexis nodosa in the temporal scalp region (Courtesy of Valerie Callender,
MD; from Treatments for Skin of Color by Susan C. Taylor, MD, et al, copyright Elsevier 2011).Bregfeld, 2001; Samrao et al., 2010a, 2011; Rollins, 1961; Fox et al., 2007;
Tosti et al., 2010; Mirmirani and Khumalo, 2014; Ahdout andMirmirani,
2012; Trueb, 1995; Heath and Taylor, 2012; James et al., 2007; Callender
et al., 2004; Khumalo and Ngwanya, 2007; Ozcelik, 2005; Martin and
Sugathan, 2011), such as from harsh hair combing practices, chemical
trauma, excessive brushing, and application of heat. While acquired TN
usually affects the distal shaft, there has been a recently reported case
of recurrent generalized proximal trichorrhexis nodosa in a Nigerian
female with a history of severe atopic dermatitis, affecting the scalp
(Ogunbiyi et al., 2014). Occasionally, acquired TN may also result from
iron deﬁciency or hypothyroidism (Lurie et al., 1996).
Chemical trauma to the hair includes excessive exposure to bleaching,
perming, shampooing and dyeing. In African type hair, chemical
“relaxers” are used to straighten the tightly curled hair. In addition to
disrupting the hair cuticle, these relaxers also reduce cysteine levels
within the hair shaft (Khumalo et al., 2010). Cysteine is a component of
the disulﬁde bonds that are responsible for the inherent strength of hair
(Khumalo et al., 2010).
Heating devices such as hot combs andﬂat irons are used, not only in
African Americans, but in all ethnic groups, to obtain sleek, straight hair
(Khumalo et al., 2010). Here, hydrogen bonds in the cortex of the hair
shaft are temporarily broken and then reform (Bolduc and Shapiro,
2001; Quinn et al., 2003). Unfortunately, damage to the protective
cuticle is a common consequence; with hair breakage reported in up
to 18% of African American women using a hot comb (Grimes, 2000).
Treatment of acquired trichorrhexis nodosa focuses on avoiding the
offending agents. Patients should be advised to use combs with straight
elongated bristles, along with hair oils and conditioners, to minimize
tension and friction along the hair shaft. In chemical induced TN, hair
relaxers and dyes should be applied only by a licensed professional.
Patients should be advised of the signiﬁcantly increased risk of hair
breakage when dyeing chemically straightened hair. Also, hot combs
and ﬂat irons should be used no more frequently than once per week,
on dry hair only, at temperatures below 175°C (Mirmirani, 2010;
Detwiler et al., 1994; Ruetsch and Kamath, 2004).
Central Centrifugal Cicatricial Alopecia
Central Centrifugal Cicatricial Alopecia (CCCA), a chronic, progres-
sive and inﬂammatory form of hair loss, seen more commonly in
women of African descent and rarely in men (Sperling and Sau, 1992).
It has been previously known as “follicular degeneration syndrome,”
“hot comb alopecia,” and chemically induced scarring alopecia
(Sperling and Sau, 1992; LoPresti et al., 1968; Nicholson et al., 1993).
The currently recognized term, CCCA, was later coined by the North
American Hair Research Society (NAHRS) (Olsen et al., 2003).
The true prevalence of this condition is still unknown but may vary
from 2.7% to 5.7% and increases with age (Ogunleye et al., 2014).
However, it has been reported that CCCA patients are among the top
ﬁve reasons why African- Americans seek dermatologic evaluation
(Halder et al., 1983b; Alexis et al., 2007). The true etiology of CCCA
remains to be elucidated and is most likely multifactorial. Possible
contributing factors include intense heat and traction to the scalp, the ap-
plication of chemical relaxers, the intrinsically curly nature of African
hair follicles and the decreased number of dermal elastic ﬁbers in
African hair compared with that of white individuals (Nicholson et al.,
1993; Gathers et al., 2009; Nnoruka, 2005; Ackerman et al., 2000;
Montagna and Carlisle, 1991). Genetics also appears to play a signiﬁcant
role, and an autosomal dominant inheritance pattern with partial pene-
trance has been proposed (Dlova and Forder, 2012; Dlova et al., 2014).
Lastly, the intrinsically curly nature of African hair follicles likely plays a
role in CCCA development. African hair is elliptical in nature, with fre-
quent twists and decreased tensile strength (Franbourg et al., 2003).
This intrinsic risk for breakage is compoundedwith harsh hair grooming
practices which force the hair to ﬂow in an unnatural direction for
prolonged periods of time (Callender and Onwudiwe, 2011).
Fig. 11. Early stage CCCA (Courtesy of Susan C. Taylor,MD, et al; from Treatments for Skin of
Color, copyright Elsevier 2011).
Fig. 13.CCCA in anAfrican Americanwoman (Courtesy of Jean Bolognia,MD; fromDerma-
tology, copyright Elsevier, 3rd ed., 2012).
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scalp with symmetric spread in a centrifugal pattern (Figs. 11-13). The
clinical presentation and distribution of hair loss may mimic that of
androgenetic alopecia, but the lack of follicular openings indicates a
scarring process (Fig. 14). Possible signs and symptoms include papules,
pustules, tenderness or pruritus of the scalp and may be totally asymp-
tomatic. A sign of early or occult CCCA may present as hair breakage
(Callender et al., 2012b). While patients may not have frank alopecia
at presentation, a history of short, broken hair should prompt further
investigation and a conﬁrmatory biopsy. Dermatoscopic evaluation
may aid in identifying the optimal site from which to obtain a biopsy
specimen. On dermoscopy, the presence of a peripilar white halo is a
feature that suggests CCCA in an African American patient with mild
central thinning. The peripilar white halo corresponds on pathology to
the lamellar ﬁbrosis surrounding the outer root sheath (Miteva and
Tosti, 2013, 2014).
In terms of associated disorders and hair grooming practices, results
of a cross-sectional survey by Kyei et al found a statistically signiﬁcant
correlation with type 2 diabetes mellitus, bacterial skin infections and
hairstyles like braids andweaves. Interestingly, no signiﬁcant difference
was noted in the use of chemical relaxers and hot combs. Therewas also
a strong positive correlation between the age of the subjects and degree
of hair loss (Kyei et al., 2011). A study by Olsen et al found no signiﬁcantFig. 12. CCCA (Courtesy of Susan C. Taylor, MD, et al; from Treatments for Skin of Color,
copyright Elsevier 2011).correlation between chemical relaxer and hot combuse, seborrheic der-
matitis, or bacterial infections (Olsen et al., 2011).
Treatment of CCCA is focused on attempting to terminate the
progression of disease with hopes of possible regrowth if permanent
scarring has not occurred. Firstly, discontinuationof potentially damaging
hair-grooming practices should be encouraged. High potency topical
corticosteroids or intralesional corticosteroid injections may help
with symptom alleviation. For active spreading disease, anti-
inﬂammatory antibiotics such as doxycycline and antimalarials such
as hydroxychloroquinemay slowdisease activity (Summers et al., 2011).
In patientswith stable disease controlledwithmedical therapy for at
least one year, and who also display a lack of inﬂammation on scalp
biopsy, hair transplantation can be a safe well-tolerated procedure for
CCCA in women of color (Callender et al., 2014b). However, it is impor-
tant to note that the presence of scarring can decrease the transplanted
graft survival rate, and regrowth of the transplanted hair is slow
(Callender, 2006; Callender and Young, 2008). Counseling includes
styles that seek to camouﬂage the injury including wigs, color sticks/
crayons or micropigmentation (Callender et al., 2004).
Frontal Fibrosing Alopecia
Frontal ﬁbrosing alopecia (FFA), ﬁrst described in 1994 (Kossard,
1994), is a primary scarring alopecia that is considered a clinical variant
of lichen planopilaris (Kossard et al., 1997). It occursmainly in postmeno-
pausal women (Kossard, 1994), although premenopausal women
(Moreno-Ramirez and Camacho Martinez, 2005; Faulkner et al., 2002;
Banka et al., 2014; Vañó-Galván et al., 2014) andmen (Kossard and Shiell,
2005; Nusbaum and Nusbaum, 2010; Stockmeier et al., 2002; Dlova and
Goh, 2013; Ramaswamy et al., 2012) may also be affected.
Most data on FFA comes from studies and case reports including a
majority of white and Asian patients. It is important to note that, al-
though uncommon, FFA does occur in individuals of African descent
(Miteva et al., 2012; Dlova et al., 2013). This lack of data on FFA in
black patients may be due to misdiagnosis as traction alopecia (Miteva
et al., 2012), which has overlapping clinical features with FFA and is a
very common entity in this patient population.
On presentation, there is follicular hyperkeratosis, perifollicular ery-
thema and scarring of the frontotemporal hairline (Fig. 15). Up to 75% of
patients may also complaint of eyebrow loss, which may be the initial
Fig. 14. Late stage CCCA (Courtesy of Susan C. Taylor, MD, et al; from Treatments for Skin of
Color, copyright Elsevier 2011).
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2009; Samrao et al., 2010b). Other affected areas include the eyelashes,
axillary and pubic regions, the occipital scalp, and vellus hairs, which
may present as facial noninﬂammatory papules, or follicular red dots
in the glabellar region (Ladizinski et al., 2013; Tan and Messenger,
2009; Samrao et al., 2010b; Chew et al., 2010; Molina et al., 2011;
Pirmez et al., 2014). Furthermore, it has been proposed that the
triad of eyelash loss, body hair involvement, and facial papules is
associated with severe FFA, and may be used to predict prognosis
and to highlight patients who would require systemic therapy
(Vañó-Galván et al., 2014).
An interesting clinical ﬁnding of FFA is termed the “lonely hair sign”
(Tosti et al., 2011). There has been debate as to whether this sign is
speciﬁc to FFA, as it is common to see hairs that are spared from the
inﬂammatory processes in all types of cicatricial alopecias (Camacho,
2012). However, it is important to note that this term describes the
presence of one or few isolated terminal hairs, particularly in themiddle
of the forehead; as FFA is the only cicatricial alopecia characterized by
progressive recession of the frontotemporal hairline (Tosti, 2012).
Another useful tool in the diagnosis of FFA is dermoscopy (Inui et al.,Fig. 15. FFA in an African American female. Note the symmetrical band-like loss of hair on
the frontotemporal hairline and scalp. (Courtesy of Valerie Callender, MD; Callender
Dermatology & Cosmetic Center, Glenn Dale, MD).2008);which shows loss of follicular oriﬁces and perifollicular erythema,
a direct marker of FFA activity (Toledo-Pastrana et al., 2013).
Several disorders reported to possibly be associated with FFA in-
clude thyroid disease, vitiligo, lichen planus pigmentosus, lupus erythe-
matosus (MacDonald et al., 2012; Miteva et al., 2011; Berliner et al.,
2014; Del Rei et al., 2014; Khan et al., 2013; Dlova, 2013; Gaffney
et al., 2013). Lichen planus pigmentosus has been identiﬁed as a herald
sign for imminent FFA in black South African patients (Dlova, 2013).
Because of the signiﬁcant prevalence of hypothyroidism in FFA subjects
in the their study, Vañó-Galván et al strongly suggest including thyroid
hormone laboratory studies in the initial workup of patients with FFA
(Vañó-Galván et al., 2014).
While there are presently no clinical trials for the management of
FFA, several treatments have been reported. These include topical
and intralesional corticosteroids, topical calcineurin inhibitors,
hydroxychloroqine, mycophenolatemofetil and oral 5-alpha reductase
inhibitors (5aRi) (Moreno-Ramirez and Camacho Martinez, 2005;
Samrao et al., 2010b; Tan et al., 2004; Katoulis et al., 2009; Chiang
et al., 2010; Cho et al., 2010). The efﬁcacy of these treatment modalities
are inconsistent. In patients who do not undergo any treatment, re-
cession of the anterior hairline ranges from 0.95-1.08 cm per year
(Toledo-Pastrana et al., 2013; Miteva and Tosti, 2012). Before initiating
treatment, it is important that the patient understands that the main
goal is to halt progression of hair loss. In reported cases of improvement,
hair regrowth was minimal, and always located at the hairline.
In recently published reviews, oralﬁnasteride or dutasteride showed
good response in 44-47% (Vañó-Galván et al., 2014; Racz et al., 2013).
This was followed by intralesional steroids and oral antimalarials.
Therefore, it has been suggested that 5aRi may be a useful maintenance
treatment to stabilize FFA (Ladizinski et al., 2013), and can be used
together with intralesional corticosteroids when signs of activity such
as perifollicular erythema or follicular hyperkeratosis are present
(Vañó-Galván et al., 2014).
Conclusion
People of color constitute a large group that will continue to expand.
This article has reviewed the most updated, evidence-based literature
regarding the pathophysiology and treatment of disorders prevalent
in women of color, particularly acne, melasma and alopecia. Important
biological differences in skin and hair structure do exist in individuals
of color and this may account for the increased incidence of keloids
and pigmentary disorders. Prompt diagnosis and initiation of targeted
therapy is imperative as these steps may prevent the potential sequelae
common in women of color such as dyschromias and scarring.
In general, the pathogenesis and treatments for acne in women of
color are similar to the general population; however, there are a few
special considerations. Given the increased risk of PIH and keloid scar-
ring in women with darker skin types, early aggressive reduction of in-
ﬂammation is essential in treatment. Therefore, dermatologists should
consider topical or oral agents with prominent anti-inﬂammatory
effects to reduce acne-associated inﬂammation. In addition, in order to
avoid exacerbation of PIH, physicians must be cautious with the selec-
tion of topical acne agents that are known to cause irritation. Sun pro-
tective measures, as well as effective skin lightening agents such as
hydroquinone and azelaic acid, are important adjunctive therapies in
the treatment of PIH.
The tendency for skin of color to develop PIH also limits the therapeu-
ticmodalities formelasma. Topical and aesthetic procedures are typically
used in combination to achieve the best cosmetic outcome.While topical
therapies remain theﬁrst choice in therapy, chemical peels and lasers are
the second and third lines of management, respectively.
In women of color, particularly African Americans, a basic under-
standing of the diverse hair care practices is essential as many alopecias
in this patient population may be associated with unique culturally-
related hair styling methods. CCCA is the most common primary
73C.N. Lawson et al. / International Journal of Women's Dermatology 1 (2015) 59–75scarring alopecia in African American women. While topical and
intralesional corticosteroids, oral anti-inﬂammatory agents and hair
transplantation are potential treatments, patient education is para-
mount to halt progression of the disease process. As our understanding
of these common dermatological disorders in women of color continue
to unfold, advances in treatment are likely to develop.
Appendix A. US Preventive Services Task Force levels of evidence for
grading clinical trials (Sheth and Pandya, 2011b)Level of
evidence
Quality of evidence
I Evidence obtained from at least one properly designed, randomized
controlled trial
II-i Evidence obtained from well designed controlled trials without
randomization
II-ii Evidence obtained from well designed cohort or case control
analytical studies, preferably from more than one center or
research group
II-iii Evidence obtained from multiple time series with or without the
intervention; dramatic results in uncontrolled experiments could
also be regarded as this type of evidence
III Opinions of respected authorities based on clinical experience,
descriptive studies, or reports of expert committees
IV Evidence inadequate because of problems of methodology (eg, sample
size or length of comprehensiveness of follow-up or conﬂicts in
evidence)
Strength of recommendations
A There is good evidence to support the use of the procedure
B There is fair evidence to support the use of the procedure
C There is poor evidence to support the use of the procedure
D There is fair evidence to support the rejection of the use of the procedure
E There is good evidence to support the rejection of the use of the procedureReferences
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